🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At what point did we stop caring and start accepting that a significant number of Americans don't have access to clean drinking water? edition.cnn.com/2018/11/28/hea…

Trust me, I am lying with your data cocodong.com/2018/11/29/tru…

The power of simplicity cocodong.com/2018/11/30/the…

I have completed my challenge of 100 books! goodreads.com/user_challenge…

jessicadewitt.wordpress.com/2018/12/10/wha…

Is medical school a good investment? Answer this with R cocodong.com/2018/12/18/is-…

The power of consistency cocodong.com/2018/12/19/the…

It’s the most wonderful time of the year 🥳🥳🥳 #10ksmallbiz #holidaymarket @ 200 West Street instagram.com/p/Brl8I95BUHs/…

Simply Bayesian cocodong.com/2018/12/21/sim…

P value? cocodong.com/2019/09/04/p-v…

p53 - the guardian of the genome - has long been a compelling but highly challenging anticancer drug target. Find out about the latest progress in the field in this news article by Asher Mullard published today go.nature.com/2AVyqAq

For more on kinases as targets for cancer and other indications, here's a comprehensive review go.nature.com/2WHfxJs

Find out more about how gene editing technologies are being used to improve the characteristics of cell therapies in this review from the July issue rdcu.be/b5rYm

mRNA platforms are at the forefront of efforts to develop vaccines for COVID19 - here's a new article on the intellectual property landscape go.nature.com/2X2iJzp and a review on the technology go.nature.com/38YrjDQ

In a validation data set of 752 biopsy specimens, the rate of agreement with gleason grade defined by subspecialists was significantly higher for a deep learning system than it was for a cohort of general pathologists: jamanetwork.com/journals/jamao… #AI #PCSM

Congrats to Andrew Thompson & Simon Mead on this exciting medRxiv: medrxiv.org/content/10.110… - incredible patience to assemble 12 years of data on plasma biomarkers in prion disease! Blog post coming soon.

Jim Albert and I created a set of pdf slides with Rmd for all 13 chapters of our book. All pdf and Rmd files are available here: monika76five.github.io/ProbBayes/ We hope these will help potential instructors with their course design! Let us know if you have any feedback and thanks!

p53 - the ‘guardian of the genome’ - has been extensively pursued as anticancer target. Could immuno-oncology combinations, stapled peptides and targeted degraders unleash its potential? go.nature.com/39HV8ci Find out in this news article by Asher Mullard in the August issue

Former prion disease drug candidate anle138b, now being developed for synucleinopathies, has cleared Phase I: businesswire.com/news/home/2020…

U.S. FDA approves GlaxoSmithKline's blood cancer drug cnbc.com/2020/08/06/us-…